Get Diamond plan for FREE

    logo

    Moolec Science S.A. (MLECW)

    Price:

    0.06 USD

    ( + 0.02 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    MLECW
    Name
    Moolec Science S.A.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    0.055
    Market Cap
    599.049k
    Enterprise value
    286.829M
    Currency
    USD
    Ceo
    Alejandro Antalich
    Full Time Employees
    52
    Ipo Date
    2023-01-03
    City
    Luxembourg
    Address
    17 Boulevarrd F.W. Raiffeisen,

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    BioNTech SE

    VALUE SCORE:

    6

    Symbol
    BNTX
    Market Cap
    22.626B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    3.694B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    12

    Symbol
    HRMY
    Market Cap
    1.624B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -9.647
    P/S
    2.789
    P/B
    14.981
    Debt/Equity
    7.897
    EV/FCF
    -13.417
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    7.588
    Earnings yield
    -0.104
    Debt/assets
    0.704
    FUNDAMENTALS
    Net debt/ebidta
    -9.076
    Interest coverage
    -3.427
    Research And Developement To Revenue
    0.172
    Intangile to total assets
    0.298
    Capex to operating cash flow
    -0.178
    Capex to revenue
    0.085
    Capex to depreciation
    0.575
    Return on tangible assets
    -0.197
    Debt to market cap
    1.886
    Piotroski Score
    3.000
    FUNDAMENTALS
    PEG
    1.946
    P/CF
    -19.951
    P/FCF
    -4.735
    RoA %
    -13.839
    RoIC %
    -15.147
    Gross Profit Margin %
    -15.705
    Quick Ratio
    0.728
    Current Ratio
    1.478
    Net Profit Margin %
    -103.401
    Net-Net
    -8.539
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.914
    Revenue per share
    1.617
    Net income per share
    -1.672
    Operating cash flow per share
    -0.776
    Free cash flow per share
    -0.914
    Cash per share
    0.743
    Book value per share
    1.077
    Tangible book value per share
    -2.518
    Shareholders equity per share
    1.077
    Interest debt per share
    8.971
    TECHNICAL
    52 weeks high
    0.079
    52 weeks low
    0.012
    Current trading session High
    0.079
    Current trading session Low
    0.012
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.142
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.680
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.004
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.936
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.121
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.403
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.546
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.314
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.666
    logo

    Country
    TW
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -9.238
    DESCRIPTION

    Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.

    NEWS
    https://images.financialmodelingprep.com/news/moolec-science-mlec-stock-explodes-90-after-gla-update-20260213.jpg
    Moolec Science (MLEC) Stock Explodes 90% After GLA Update

    benzinga.com

    2026-02-13 10:11:08

    The program produced oil with about 45% gamma-linolenic acid after standard U.S. crushing, which the company says is among the highest levels reported at commercial scale.

    https://images.financialmodelingprep.com/news/moolec-science-granted-continued-listing-on-nasdaq-subject-to-20260130.jpg
    Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions

    accessnewswire.com

    2026-01-30 16:20:00

    GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 30, 2026 / Moolec Science S.A. ("Moolec" or the "Company"), a science-based food ingredient company focused on scalable protein solutions for the global market, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions.

    https://images.financialmodelingprep.com/news/moolec-science-sa-receives-nasdaq-staff-memo-supporting-panel-20260123.jpg
    Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

    accessnewswire.com

    2026-01-23 18:30:00

    GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 23, 2026 / Moolec Science S.A. ("Moolec" or the "Company") today announced that Nasdaq Staff has issued a memorandum to the Nasdaq Hearings Panel (the "Panel") concluding that there is sufficient basis to grant Moolec an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), subject to certain disclosure conditions.

    https://images.financialmodelingprep.com/news/moolec-science-sa-receives-nasdaq-panel-exception-through-june-20260122.jpg
    Moolec Science S.A. Receives Nasdaq Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

    accessnewswire.com

    2026-01-22 09:20:00

    GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 22, 2026 / Moolec Science S.A. ("Moolec" or the "Company") today announced that it has received a decision from the Nasdaq Hearings Panel (the "Panel") granting the Company an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), subject to certain disclosure conditions.

    https://images.financialmodelingprep.com/news/moolec-science-announces-effectiveness-of-share-consolidation-20260105.jpg
    Moolec Science Announces Effectiveness of Share Consolidation

    accessnewswire.com

    2026-01-05 21:00:00

    GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 5, 2026 / Moolec Science SA ("Moolec" or the "Company") today announced that, in accordance with the resolutions passed at the extraordinary general meeting of shareholders held on December 16, 2025, and the resolutions adopted by the Company's board of directors on December 19, 2025, the Company has consummated, effective as of January 5, 2026, the previously announced share consolidation at a ratio of 15-for-1, so that all shareholders holding every 15 ordinary shares of par value of US$0.10 each will hold 1 ordinary share of par value US$1.50 each (the "Share Consolidation"). As a result, every 15 ordinary shares of the Company, par value US$0.10 per share each (with par value to be amended from time to time, the "Shares"), issued and outstanding immediately prior to the Share Consolidation, were automatically consolidated into 1 validly issued, par value US$1.50 each, fully paid and non-assessable Share, without any action required by any shareholder.

    https://images.financialmodelingprep.com/news/moolec-receives-staff-determination-letter-and-provides-update-on-20251231.jpg
    Moolec Receives Staff Determination Letter and Provides Update on Nasdaq Listing Compliance Status

    accessnewswire.com

    2025-12-31 18:00:00

    GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / December 31, 2025 / Moolec Science SA ("Moolec" or the "Company") received an additional determination letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company does not currently meet the minimum stockholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1). As previously disclosed in the Company's Form 20-F for the year ended June 30, 2025, management expects to regain compliance with the Nasdaq continued listing standards through the recognition of an estimated gain of approximately $105.8 million related to the derecognition of certain subsidiaries following their bankruptcy proceedings.

    https://images.financialmodelingprep.com/news/moolec-receives-nasdaq-determination-letter-20251128.jpg
    Moolec Receives Nasdaq Determination Letter

    accessnewswire.com

    2025-11-28 13:15:00

    GRAND CAYMAN, CAYMAN ISLANDS / ACCESS Newswire / November 28, 2025 / On November 24, 2025, Moolec Science SA ("Moolec" or the "Company") received a letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 20-F for the year ended June 30, 2025 (the "Form 20-F") with the Securities and Exchange Commission (the "SEC"). As the Company stated in the form 12b-25 filed with the SEC on October 31, 2025, it was unable to file the Form 20-F in a timely manner due to complexities that arose immediately after the closing of the business combination in mid-June 2025, two weeks prior to Moolec's fiscal year end of June 30.

    https://images.financialmodelingprep.com/news/moolec-science-mlec-q4-2024-earnings-call-transcript-20241002.jpg
    Moolec Science (MLEC) Q4 2024 Earnings Call Transcript

    seekingalpha.com

    2024-10-02 12:37:10

    Moolec Science SA (NASDAQ:MLEC ) Q4 2024 Earnings Conference Call October 2, 2024 8:30 AM ET Company Participants Gaston Paladini - Chief Executive Officer Jose Lopez Lecube - Chief Financial Officer Martin Salinas - Chief Technology Officer Amit Dhingra - Chief Science Officer Bill Zima - ICR Strategic Communications Conference Call Participants Scott Fortune - Roth Capital Operator Good morning and welcome to Moolec Science's fourth quarter and full fiscal year 2024 conference call. My name is Bill Zima of ICR Strategic Communications and Advisory.

    https://images.financialmodelingprep.com/news/why-is-moolec-science-mlec-stock-up-121-today-20240422.jpg
    Why Is Moolec Science (MLEC) Stock Up 121% Today?

    investorplace.com

    2024-04-22 08:01:41

    Moolec Science (NASDAQ: MLEC ) stock is taking off on Monday after the company got approval from the Food and Drug Administration (FDA) for its plant-grown animal proteins. According to a press release from the company, this covers its genetically engineered soybean that accumulates animal proteins.

    https://images.financialmodelingprep.com/news/why-is-moolec-science-mlec-stock-up-40-today-20240111.jpg
    Why Is Moolec Science (MLEC) Stock Up 40% Today?

    investorplace.com

    2024-01-11 08:27:10

    Moolec Science (NASDAQ: MLEC ) stock is getting a boost on Thursday despite a lack of news from the science-based food ingredient company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is rising today.

    https://images.financialmodelingprep.com/news/moolec-science-sa-mlec-q1-2024-earnings-call-transcript-20231214.jpg
    Moolec Science SA (MLEC) Q1 2024 Earnings Call Transcript

    seekingalpha.com

    2023-12-14 11:55:25

    Moolec Science SA (NASDAQ:MLEC ) Q1 2024 Earnings Conference Call December 14, 2023 8:30 AM ET Company Participants Michael Bowen - ICR's, Strategic Communications and Advisory Gaston Paladini - CEO and Co-Founder Amit Dhingra - Chief Science Officer Jose Lopez Lecube - CFO Conference Call Participants Brian Wright - ROTH MKM Tom McGovern - Maxim Group Michael Bowen Good morning, and welcome to Moolec's Conference Call. My name is Michael Bowen, from ICR's, Strategic Communications and Advisory.